-
公开(公告)号：KR100920856B1
公开(公告)日：2009-10-09
申请号：KR1020040099426
申请日：2004-11-30
Applicant: (주)아모레퍼시픽
CPC classification number: A61K9/2886
Abstract: 본 발명은 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그 제조방법에 관한 것으로, 본 발명에 따라 침식성 수용성 고분자, 형태유지보완성 하이드로겔 및 약제학적 첨가제로 이루어진 단일층 매트릭스에 선택적 세로토닌 재흡수 억제제가 유효량 담지된 것을 특징으로 하는 연장방출 제제는, 침식성 수용성 고분자 및 하이드로겔로 구성된 단일층 매트릭스의 침식에 의해 약물이 흡수부위에서 일정속도로 방출 및 흡수되어 혈중 약물농도의 급격한 상승을 방지하고, 국소자극을 최소화하여 부작용의 발생을 둔화시키며, 위장관 운동 등의 외부 물리적 환경에 의한 영향을 최소화하므로 안정화된 0차 방출을 제공하는 경구용 고형 제제로서 유용하게 활용될 수 있다.
-
公开(公告)号：KR1020060060371A
公开(公告)日：2006-06-05
申请号：KR1020040099426
申请日：2004-11-30
Applicant: (주)아모레퍼시픽
CPC classification number: A61K9/2886
Abstract: 본 발명은 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그 제조방법에 관한 것으로, 본 발명에 따라 침식성 수용성 고분자, 형태유지보완성 하이드로겔 및 약제학적 첨가제로 이루어진 단일층 매트릭스에 선택적 세로토닌 재흡수 억제제가 유효량 담지된 것을 특징으로 하는 연장방출 제제는, 침식성 수용성 고분자 및 하이드로겔로 구성된 단일층 매트릭스의 침식에 의해 약물이 흡수부위에서 일정속도로 방출 및 흡수되어 혈중 약물농도의 급격한 상승을 방지하고, 국소자극을 최소화하여 부작용의 발생을 둔화시키며, 위장관 운동 등의 외부 물리적 환경에 의한 영향을 최소화하므로 안정화된 0차 방출을 제공하는 경구용 고형 제제로서 유용하게 활용될 수 있다.
-
公开(公告)号：KR1020140035133A
公开(公告)日：2014-03-21
申请号：KR1020120101606
申请日：2012-09-13
Applicant: (주)아모레퍼시픽
Abstract: An electroporation device according to an embodiment of the present invention comprises: multiple electrode pins touching skin to perforate the skin; a wiring board having a wiring pattern to transmit voltage to the multiple electrode pins; a voltage generating part generating the voltage transmitted to the multiple electrode pins through the wiring pattern of the wiring board; a controlling part controlling the polarity of the voltage transmitted to the multiple electrode pins to make any neighboring electrode pins among the multiple electrode pins have different polarities in every cycle; and a voltage compensating part measuring the resistance of the skin where the multiple electrode pins touch, and compensating the voltage level transmitted to the multiple electrode pins according to the resistance level. [Reference numerals] (110) Main body; (111) Power unit; (112) Voltage generating part; (113) Controlling part; (114) Operation display part; (115) Power display part; (116) Voltage compensating part; (120) Perforating part; (121) Wiring board; (122) Electrode pin; (123) Pin guide; (130) Piezo switch
Abstract translation: 根据本发明的实施例的电穿孔装置包括：多个电极针接触皮肤以穿透皮肤; 具有向多个电极引脚传输电压的布线图案的布线板; 电压产生部件，通过布线板的布线图形产生传输到多个电极引脚的电压; 控制部分控制传输到多个电极引脚的电压的极性，使得多个电极引脚中的任何相邻的电极引脚在每个周期中具有不同的极性; 以及电压补偿部，其测量多个电极引脚接触的皮肤的电阻，并根据电阻水平补偿传输到多个电极引脚的电压电平。 （附图标记）（110）主体; （111）动力单元; （112）电压产生部; （113）控制部分; （114）操作显示部分; （115）电源显示部分; （116）电压补偿部; （120）穿孔部分; （121）接线板; （122）电极针; （123）引脚引导; （130）压电开关
-
公开(公告)号：KR1020140012336A
公开(公告)日：2014-02-03
申请号：KR1020120078921
申请日：2012-07-19
Applicant: (주)아모레퍼시픽
CPC classification number: A61M5/3298 , A61M5/20 , A61M5/204 , A61M5/2053 , A61M5/30 , A61M5/31511 , A61M5/46 , A61M37/0015 , A61M2037/0023 , A61M2037/003
Abstract: The present invention relates to a nozzle device and a minimal invasive injection device comprising the same. The nozzle device for the minimal invasive injection device by an embodiment of the present invention includes: an outlet forming a liquid microjet; and a microsized inlet connected to the outlet to be inserted into the skin tissue to a predetermined depth.
Abstract translation: 本发明涉及喷嘴装置和包括该喷嘴装置的最小侵入注射装置。 本发明的一个实施例的用于最小侵入式注射装置的喷嘴装置包括：形成液体微喷嘴的出口; 以及连接到出口的微型入口以插入皮肤组织到预定深度。
-
公开(公告)号：KR1020080076382A
公开(公告)日：2008-08-20
申请号：KR1020070016221
申请日：2007-02-15
IPC: A61K9/22 , A61K31/4709
CPC classification number: A61K9/0065 , A61K9/2031 , A61K9/2054 , A61K31/4709
Abstract: A controlled-release preparation containing cilostazol is provided to improve absorption rate of cilostazol in small intestine and reduce side effects such as headache by staying in stomach for a long time and slowly releasing cilostazol, and enhance compliance of patient by reducing dosage frequency. A controlled-release preparation contains 10-80 wt.% of cilostazol or its pharmaceutically acceptable salt, 0.1-50 wt.% of solubilizer, 5-80 wt.% of swelling agent, 0.5-50 wt.% of swelling speed-controller and 0.1-50 wt.% of gas-generating material. A method for preparing the controlled-release preparation containing cilostazol comprises the steps of: mixing cilostazol or its pharmaceutically acceptable salt, solubilizer, swelling agent, swelling speed-controller and gas-generating material; granulating the mixture; and filling the granulates in capsules or tabletting the granulates.
Abstract translation: 提供含有西洛他唑的控释制剂，以提高西洛他唑在小肠中的吸收率，并通过长时间停留在胃中并缓慢释放西洛他唑，减少头痛的副作用，并通过降低剂量频率增强患者的依从性。 控释制剂含有10-80重量％的西洛他唑或其药学上可接受的盐，0.1-50重量％的增溶剂，5-80重量％的溶胀剂，0.5-50重量％的溶胀速度控制剂 和0.1-50重量％的气体发生材料。 制备含有西洛他唑的控释制剂的方法包括以下步骤：将西洛他唑或其药学上可接受的盐，增溶剂，溶胀剂，溶胀速度控制器和产气材料混合; 制粒混合物; 并将颗粒填充在胶囊中或压制颗粒。
-
Patent Agency Ranking
公开(公告)号：KR1020040067969A
公开(公告)日：2004-07-30
申请号：KR1020040003871
申请日：2004-01-19
Applicant: (주)아모레퍼시픽
IPC: A61K9/16
CPC classification number: A61K9/2077 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K9/2095 , A61K9/2846 , A61K9/2866 , A61K31/00 , A61K31/485
Abstract: PURPOSE: Provided is a controlled release preparation which minimizes the addition of a hydrophobic material, and prevents the surface adhesion of granules. The controlled release preparation continuously releases the drug content for 12 hours while maintaining the effective drug concentration in blood. CONSTITUTION: The controlled release preparation comprises 0.5-80wt.% of drug, 10-65wt.% of a hydrophobic release control additive, and 1-35wt.% of a hydrophobic wet granulating material. The drug is first melt-granulated using the hydrophobic release control additive, and the resulting granules are second wet-granulated using the hydrophobic wet granulating material.
Abstract translation: 目的：提供一种控制释放制剂，其最小化添加疏水性材料，并防止颗粒的表面粘附。 控释制剂连续释放药物含量12小时，同时保持血液中有效的药物浓度。 构成：控释制剂包含0.5-80重量％的药物，10-65重量％的疏水释放控制添加剂和1-35重量％的疏水湿法制粒材料。 首先使用疏水性释放控制添加剂对药物进行熔融造粒，并使用疏水性湿法制粒材料将得到的颗粒进行第二次湿法造粒。
-
公开(公告)号：KR1020070103844A
公开(公告)日：2007-10-25
申请号：KR1020060035687
申请日：2006-04-20
Applicant: (주)아모레퍼시픽
IPC: A61K31/365 , A61K31/415
CPC classification number: A61K31/365 , A61K9/1652 , A61K9/2077 , A61K9/2081 , A61K9/5026 , A61K9/5084 , A61K45/06 , A61K2300/00
Abstract: A pharmaceutical composition comprising a lipase inhibitor and a lipophilic oil absorbent is provided to minimize side effects caused by dosage of the lipase inhibitor including oily spotting, oily feces, abdominal distension and gas, so that it is useful for prevention and treatment of obesity and hyperlipidemia. A pharmaceutical composition comprises (a) 100 parts by weight of a lipase inhibitor, (b) 10-5000 parts by weight of a lipophilic oil absorbent selected from hydrogenated castor oil, hydrogenated vegetable oil, glyceryl behenate, glyceryl palmitostearate and a mixture thereof, and (c) a pharmaceutically acceptable additive, wherein the lipase inhibitor is lipstatin, orlistat, panclicins, hesperidin, ebelactones, esterastin and its derivative, valilactone or a pharmaceutically acceptable salt. The hydrogenated vegetable oil is selected from hydrogenated cotton seed oil, hydrogenated palm oil and hydrogenated soybean oil.
Abstract translation: 提供包含脂肪酶抑制剂和亲油性油吸收剂的药物组合物，以最小化脂肪酶抑制剂的剂量引起的副作用，包括油性斑点，油性粪便，腹胀和气体，从而可用于预防和治疗肥胖症和高脂血症 。 药物组合物包含（a）100重量份脂肪酶抑制剂，（b）10-5000重量份选自氢化蓖麻油，氢化植物油，山嵛酸甘油酯，棕榈酸硬脂酸甘油酯及其混合物的亲油性油吸收剂， 和（c）药学上可接受的添加剂，其中所述脂肪酶抑制剂是脂抑素，奥利司他，胰蛋白酶，橙皮苷，内酯，酯酶及其衍生物，缬氨酸内酯或药学上可接受的盐。 氢化植物油选自氢化棉籽油，氢化棕榈油和氢化大豆油。
-
公开(公告)号：KR1020060053972A
公开(公告)日：2006-05-22
申请号：KR1020050066153
申请日：2005-07-21
Applicant: (주)아모레퍼시픽
IPC: A61K9/16 , A61K9/22 , A61K31/357
CPC classification number: A61K9/2027 , A61K9/2077
Abstract: 본 발명은 토피라메이트 서방성 제제 및 그의 제조방법에 관한 것이다.
즉, 본 발명은 토피라메이트 또는 그의 약제학적으로 허용가능한 염을 고체분산 첨가제를 사용하여 고체 분산법에 의해 1차 과립화 시키고, 얻어진 과립을 서방화 물질로 건식 혹은 습식과립법에 의해 2차 과립화 하여 얻은 이중 과립을 이용하여 제조됨을 특징으로 하는 서방성 제제에 관한 것이다.
서방성 제제, 고체 분산법, 이중과립, 토피라메이트-
-
公开(公告)号：KR1020130027078A
公开(公告)日：2013-03-14
申请号：KR1020120093838
申请日：2012-08-27
Applicant: (주)아모레퍼시픽
CPC classification number: C07K7/08 , C07K2319/33
Abstract: PURPOSE: A biological membrane permeable composition is provided to produce a carrying object substance with high vitality in high yield rate, and a composition with low molecular weight protamine combined to one end or both ends. CONSTITUTION: A biological membrane permeable composition includes a carrying object substance, and low molecular weight protamine. The low molecular weight protamine is combined to one or both ends of the carrying object substance, and has an amino acid sequence which has over 70% of homology to one or more of amino acid sequence with the amino acid sequence number 1 and the amino acid sequence number 2. The carrying object substance includes one or more selected from the group consisting of protein, polypeptide, peptide, nucleoacid, mRNA, and antisense RNA. The protein includes one selected from DKK-2(Dickkopf-related protein-2), adipokine, thrombospondin, and superoxide dismutase. The carrying object substance is one or more selected from growing factors, enzymes, hormones, transcription factors, toxin, antigen, and antibody. [Reference numerals] (AA) Concentration in cells(uM)
Abstract translation: 目的：提供生物膜可渗透组合物以高产率生产具有高活力的携带物质，并将低分子量鱼精蛋白组合成一端或两端。 构成：生物膜可渗透组合物包括载体物质和低分子量鱼精蛋白。 低分子量鱼精蛋白与携带对象物质的一端或两端结合，具有氨基酸序列，其氨基酸序列与氨基酸序列号1的一个或多个氨基酸序列具有超过70％的同源性，氨基酸 载体物质包括选自蛋白质，多肽，肽，核酸，mRNA和反义RNA的一种或多种。 蛋白质包括选自DKK-2（Dickkopf相关蛋白-2），脂肪因子，血小板反应素和超氧化物歧化酶的一种。 载体物质是选自生长因子，酶，激素，转录因子，毒素，抗原和抗体中的一种或多种。 （标号）（AA）细胞浓度（uM）
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.023 seconds)
